DHR Health Welcomes Neurosurgeon Dr. Inad B. Atassi

Translate to Spanish or other 102 languages!

Inad B. Atassi, M.D., F.A.C.S., is the newest physician to join DHR Health

Mega Doctor News

- Advertisement -

Edinburg, TX — DHR Health is pleased to announce that Inad B. Atassi, M.D., F.A.C.S., has joined the DHR Health Neurosurgery Institute. As part of the Neurosurgery Institute, Dr. Atassi and his team utilize the most advanced technology and surgical techniques to provide comprehensive care to both adult and pediatric patients.

Inad B. Atassi, M.D., F.A.C.S., is the newest physician to join DHR Health

Dr. Atassi is Board Certified in Neurosurgery and has over 35 years of experience.  He received his Doctor of Medicine at Damascus University in Damascus, Syria.  He completed his General Surgery residency at Henry Ford Hospital in Detroit, Michigan and continued his Neurosurgery residency training at the University of Kansas Medical Center in Kansas City, Kansas. 

The DHR Health Neurosurgery Institute is located at 1200 E. Savannah, Suite 3, McAllen where prominent physicians treat disorders such as aneurysms, brain tumors, congenital brain and spine malformations, hydrocephalus, neural tube defects, spina bifida, spinal cord tumors and more.  DHR Health Neurosurgery Institute has the only fellowship-trained spine surgeons in the region.   

- Advertisement -

For more information about the services offered at the DHR Health Neurosurgery Institute or to schedule an appointment, please call (956) 362-8500 or visit our DHR Health website, www.dhrhealth.com.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer

The U.S. Food and Drug Administration approved Rasonque (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer—delivering a new treatment option to patients with advanced pancreatic cancer months ahead of schedule. 

STHS Behavioral Marks Suicide Prevention Month with Community Chalk Event

Every 11 minutes, someone in the United States dies by suicide, according to the Centers for Disease Control and Prevention (CDC), making it one of the nation's leading causes of death.

Moderna and Merck Report Positive Phase 3 Results for Personalized Cancer Therapy

Moderna and Merck have reached a major clinical milestone after their investigational individualized cancer therapy, combined with Merck’s Keytruda, produced positive results in a Phase 3 study involving patients with high-risk melanoma.

STHS Scores Fourth Consecutive 5-Star Rating for Diabetic Care

Diabetes remains one of the nation’s most pressing health challenges, with a disease once largely associated with older adults now affecting younger populations at an alarming rate.
- Advertisement -